Company intelligence / Profile preview

RenovoDerm

Ownership: Private
Development stage: Other

Overview

RenovoDerm’s Phoenix Wound Matrix has demonstrated rapid healing rates in complex chronic and acute wounds. Clinical feedback highlights decreased inflammation and improved granulation with minimal recurrence. The product is fully synthetic—eliminating risks associated with allogeneic/xenogeneic materials—and has shown success in regenerating functional dermal tissue including sweat glands and hair follicles in veterinary studies. No published large-scale trial data was identified.

Therapeutic areas: DermatologyEndocrinologyCardiovascularInfectious Diseases
Modalities: DeviceSynthetic polymer scaffoldHydrogel-based drug delivery therapy
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on RenovoDerm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RenovoDerm.

Explore the full profile